UEEC: Just another day of anticipation for the objective we KNOW will be realized with the successful results of the FDA clinical trials for the efficacy and safety of HemoStyp® as an adjunct for management of secondary hemostasis in an operative setting.
REALISTS know that such complex trials take TIME and do not occur on investors' timetables. I am just letting my shares of UEEC sit in my account for the INEVITABLE outcome.